NCT07204093View on ClinicalTrials.gov

Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis

Active, not recruitingOBSERVATIONAL
Enrollment

138

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Endometriosis
Interventions
DRUG

Drospirenone 4 mg orally

Daily oral administration of Drospirenone 4 mg + Transdermal estradiol; continuous administration for at least 6 months.

DRUG

Dienogest 2 mg orally

Daily oral administration of Dienogest 2 mg + Transdermal estradiol; continuous administration for at least 6 months.

Trial Locations (1)

20122

Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

All Listed Sponsors
lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER